leflunomide has been researched along with Bright Disease in 7 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, the clinical effect of lamivudine combined with leflunomide and methylprednisolone in the treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN) and their influence on renal function indexes was explored." | 8.31 | Clinical Effect of Lamivudine Combined with Leflunomide and Methylprednisolone Tablets in the Treatment of Hepatitis B Virus-Associated Glomerulonephritis and Its Influence on Renal Function Indicators. ( Jiang, F; Liu, H; Xing, X; Zhang, M; Zheng, K; Zhou, C, 2023) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 7.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 7.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Leflunomide (HWA 486, a novel isoxazol derivative), shown to have potent immunosuppressant and antiinflammatory effects, was evaluated for its inhibitory and therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against rat glomerular basement membrane." | 7.68 | Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Ogawa, T, 1990) |
| "In this study, the clinical effect of lamivudine combined with leflunomide and methylprednisolone in the treatment of hepatitis B virus-associated glomerulonephritis (HBV-GN) and their influence on renal function indexes was explored." | 4.31 | Clinical Effect of Lamivudine Combined with Leflunomide and Methylprednisolone Tablets in the Treatment of Hepatitis B Virus-Associated Glomerulonephritis and Its Influence on Renal Function Indicators. ( Jiang, F; Liu, H; Xing, X; Zhang, M; Zheng, K; Zhou, C, 2023) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 3.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 3.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Leflunomide (HWA 486, a novel isoxazol derivative), shown to have potent immunosuppressant and antiinflammatory effects, was evaluated for its inhibitory and therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against rat glomerular basement membrane." | 3.68 | Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Ogawa, T, 1990) |
| "LEF at a dosage of 30 mg/day appears to be effective in the prevention of major relapses in WG, however, this is associated with an increased frequency of adverse events." | 2.73 | Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. ( de Groot, K; Gross, WL; Hellmich, B; Iking-Konert, C; Manger, K; Metzler, C; Miehle, N; Reinhold-Keller, E, 2007) |
| "Gender, age, and hypertension are associated with KD recurrence." | 1.43 | Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Jiang, F | 1 |
| Zheng, K | 1 |
| Zhang, M | 1 |
| Xing, X | 1 |
| Zhou, C | 1 |
| Chen, Y | 1 |
| Wang, J | 1 |
| Xu, F | 1 |
| Zeng, C | 1 |
| Liu, Z | 1 |
| Deng, F | 1 |
| Zhang, P | 1 |
| Feng, J | 1 |
| Wang, L | 1 |
| Metzler, C | 1 |
| Miehle, N | 1 |
| Manger, K | 1 |
| Iking-Konert, C | 1 |
| de Groot, K | 1 |
| Hellmich, B | 1 |
| Gross, WL | 1 |
| Reinhold-Keller, E | 1 |
| Kemp, E | 1 |
| Nielsen, H | 1 |
| Petersen, LJ | 1 |
| Gam, AN | 1 |
| Dahlager, J | 1 |
| Horn, T | 1 |
| Larsen, S | 1 |
| Olsen, S | 1 |
| Ogawa, T | 2 |
| Inazu, M | 2 |
| Gotoh, K | 2 |
| Inoue, T | 1 |
| Hayashi, S | 2 |
1 trial available for leflunomide and Bright Disease
| Article | Year |
|---|---|
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
Topics: Administration, Oral; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; C-Reactive Protein; Cyclo | 2007 |
6 other studies available for leflunomide and Bright Disease
| Article | Year |
|---|---|
Clinical Effect of Lamivudine Combined with Leflunomide and Methylprednisolone Tablets in the Treatment of Hepatitis B Virus-Associated Glomerulonephritis and Its Influence on Renal Function Indicators.
Topics: Glomerulonephritis; Hepatitis B virus; Humans; Interleukin-4; Kidney; Lamivudine; Leflunomide; Methy | 2023 |
Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients.
Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; China; Fem | 2016 |
[Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis].
Topics: Animals; Chronic Disease; Disease Models, Animal; Glomerulonephritis; Inflammation; Interleukin-6; I | 2016 |
Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Female; Glomerulonephritis; Humans; I | 2001 |
Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Azathioprine; Basement | 1991 |
Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Basement Membrane; Cell Division; Complement C3; F | 1990 |